M2 Pharma - Therapy Areas

Gan & Lee Pharmaceuticals announces completion of two insulin glargine phase three studies

15 October 2021 - Gan & Lee Pharmaceuticals Co. Ltd (Shanghai: 603087.SH), a China-based manufacturer and distributer of pharmaceutical products, announced on Thursday that it has completed two ra...

Novartis's Beovu(R) receives FDA and EMA filing acceptances for patients with diabetic macular edema

14 October 2021 - Novartis announced on Wednesday that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and that the European...

US Merck, Ridgeback Submit Emergency Use Authorization Application to the US FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

12 October 2021 - - US-based pharmaceutical company Merck (NYSE: MRK) has submitted an Emergency Use Authorization application to the US Food and Drug Administration for molnupiravir, an investigation...

TEAMFund honours Baobab Circle

11 October 2021 - TEAMFund (Transforming Equity and Access in Medtech), a US-based organisation that says it combines a non-profit with an impact fund limited partnership, with a shared aim to expand ...

First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

5 October 2021 - - The first patient has been dosed with SAB-185 in the Phase 3 ACTIV-2 COVID-19 trial, US-based biopharmaceutical company SAB Biotherapeutics said.

SAB-185 is a fully hum...

Isarna Therapeutics Names Schalper as CEO

1 October 2021 - - Germany-based antisense therapies developer Isarna Therapeutics has appointed Claus Schalper as chief executive officer, the company said.

Schalper joins Isarna wi...